Wednesday, March 10, 2010
CELLCENTRIC LIMITED is pioneering novel approaches to generate therapeutics, principally for the treatment of degenerative disorders and cancer. The products are based on the world-leading research led by Professor Azim Surani FRS at the University of Cambridge. The technology and ensuing intellectual property will underpin a strong product pipeline.
The company will focus on those factors and drugs modulating their activity that will induce tissue repair and replacement for the treatment of diseases such as diabetes, CNS and blood-related disorders. They are also expected to have utility in the treatment of other diseases, such as cancer.
